Article not rated

Vol. 19 - Num. 73

Consensus document

Spanish adaptation of the 2016 European guidelines on cardiovascular disease prevention in clinical practice

Miguel Ángel Royo Bordonadaa, Pedro Armariob, José María Lobos Bejaranoc, Juan Pedro Botetd, Fernando Villar Álvarezd, Roberto Elosuae, Carlos Brotons Cuixartc, Olga Cortés Ricof, Benilde Serranog, Miguel Camafort Babkowskih, Antonio Gil Núñezi, Antonio Pérezj, Antonio Maiques Galánk, Ana de Santiago Nocitol, Almudena Castrom, Eduardo Alegría Ezquerran, Ciro Baezao, María Herranzp, Susana Sansq, (CEIPC) en nombre del Comité Español Interdisciplinario para la Prevención Cardiovascularr

abEscuela Nacional de Sanidad. Instituto de Salud Carlos III. Madrid. España.
bSociedad Española de Hipertensión-Liga Española de la Lucha Contra la Hipertensión Arterial.
cSociedad Española de Medicina de Familia y Comunitaria.
dSociedad Española de Arteriosclerosis.
eSociedad Española de Epidemiología .
fPediatra. CS Canillejas. Madrid. España.
gSociedad Española de Medicina y Seguridad en el Trabajo.
hSociedad Española de Medicina Interna.
iSociedad Española de Neurología .
jSociedad Española de Diabetes.
kSociedad Española de Medicina de Familia y Comunitaria. Madrid. España.
lSociedad Española de Médicos de Atención Primaria-Semergen .
mSociedad Española de Cardiología.
nSección de Riesgo Vascular y Rehabilitación Cardiaca. Sociedad Española de Cardiología. Madrid. España.
oSociedad Española de Angiología y Cirugía Vascular.
pFederación de Asociaciones de Enfermería Comunitaria y Atención Primaria .
qSociedad Española de Salud Pública y Administración Sanitaria.
rComité Español Interdisciplinario para la Prevención Cardiovascular.

Reference of this article: Royo Bordonada MA, Armario P, Lobos Bejarano JM, Pedro Botet J, Villar Álvarez F, Elosua R, et al. Spanish adaptation of the 2016 European guidelines on cardiovascular disease prevention in clinical practice. Rev Pediatr Aten Primaria. 2017;19:e1-e25.

Published in Internet: 13-01-2017


The VI European Guidelines for Cardiovascular Prevention recommend combining population and high-risk strategies with lifestyle changes as a cornerstone of prevention, and propose the SCORE function to quantify cardiovascular risk. The guidelines highlight disease specific interventions, and conditions specific to women, young people and ethnic minorities. Screening for subclinical atherosclerosis with noninvasive imaging techniques is not recommended. The guidelines distinguish four risk levels (very high, high, moderate and low) with therapeutic objectives for lipid control according to risk. Diabetes mellitus confers a high risk, except for subjects with type 2 diabetes with less than ten years of evolution, with no other risk factors or complications, or type 1 diabetes of short evolution without complications. The decision to start pharmacological treatment of arterial hypertension will depend on the blood pressure level and cardiovascular risk, taking into account the lesion of target organs. The guidelines do not recommend antiplatelet drugs in primary prevention because of the increased risk of bleeding. The low adherence to the medication requires simplified therapeutic regimes and identifying and combating its causes. The guidelines highlight the responsibility of health professionals to play an active role in promoting evidence-based interventions at the population level, and propose effective interventions, both at individual and population level, to promote a healthy diet, the practice of physical activity, the cessation of smoking and the protection against alcohol abuse..


Alcohol drinking Cardiovascular diseases Cholersterol Diabetes mellitus Hypertension Practice guidelines Prevention and control Tobacco Trans fatty acids



This article has no comments yet.